Drugs / CMV-TCR transduced donor-derived T cells
CMV-TCR transduced donor-derived T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02988258 | Jul 2013 → Aug 2019 | cytomegalovirus infection, hematopoietic and lymphoid cell neoplasm | University College, London | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-TCR transduced donor-derived T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02988258 ↗ |
| Modality | Cell therapy | “CMV TCR-transduced T cells” NCT02988258 ↗ |